Efficacy and Safety of SHR2285 Tablets Following Multiple Oral Administrations in Patients Undergoing Elective Total Knee Arthroplasty: a Multicenter, Randomized, Positive-controlled Phase II Clinical Study
Latest Information Update: 06 Mar 2024
At a glance
- Drugs SHR 2285 (Primary) ; Enoxaparin sodium
- Indications Deep vein thrombosis; Postoperative complications; Pulmonary embolism; Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shanghai Hengrui Pharmaceutical
Most Recent Events
- 18 Mar 2022 Status changed from not yet recruiting to recruiting.
- 28 Jan 2022 New trial record